Peripheral blood T cell alterations in newly diagnosed diffuse large B cell lymphoma patients and their long-term dynamics upon rituximab-based chemoimmunotherapy

摘要: The importance of T cell-dependent immune responses in achieving long-term cure chemoimmunotherapy-treated cancer patients is underscored by the recently described "vaccinal effect" exerted therapeutic mAbs. In accordance, pre- and post-therapy peripheral blood lymphopenia represents a well-established negative prognostic factor DLBCL. We analyzed phenotypic functional (IFNγ production, Granzyme B (GrzB) cytotoxic granule marker expression) profile lymphocyte subsets ("conventional" CD4+ CD8+, FOXP3+CD25bright Treg, "innate-like" CD56+) DLBCL at diagnosis, assessed impact R-CHOP chemoimmunotherapy, prospective study. At showed lower counts, due to selective decrement (including Treg) lymphocytes. While all cell transiently decreased during therapy, Treg remained significantly than controls, up 1 year after R-CHOP. Phenotypically skewed CD8+ associated with higher frequencies IFNγ+ GrzB+ cells that re-attained persistently elevated levels, till therapy. Differently, pre-therapy levels circulating monocytes, plasma IL-6 IL-10 rapidly normalized upon sum, we describe quantitatively functionally altered status compartment persists tumor eradication, it only perturbed chemoimmunotherapy. Moreover, data suggest association selected features phenotype, therapy outcome.